A phase 2 study of botensilimab and AGEN1423, an anti-CD73-TGFβ-trap bifunctional antibody, in subjects with advanced pancreatic cancer.
| Publicado en: | Journal of Clinical Oncology Vol. 44; pp. 702 - 847 |
|---|---|
| Autores principales: | , , , , , , , , , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
American Society of Clinical Oncology
2026 Supplsmsnr 2
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=190829662&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 190829662 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 0732183X 20D jtl: Journal of Clinical Oncology issn: 0732183X maglogo: N pubinfo: dt: 2026 Supplsmsnr 2 vid: 44 pid: 26892 pub: American Society of Clinical Oncology place: Alexandria, Virginia artinfo: ui: 190829662 10.1200/JCO.2026.44.2_suppl.702 190829662 ppf: 702 ppct: 145 formats: tig: atl: A phase 2 study of botensilimab and AGEN1423, an anti-CD73-TGFβ-trap bifunctional antibody, in subjects with advanced pancreatic cancer. aug: au: Berg, Julia Bullock, Andrea J. Whooley, Peter D. Peters, Mary Linton Bounetheau Horick, Nora K. Zerillo, Jessica Ann Rattani, Ahmed Anwer Ali Schlechter, Benjamin L. Sinanovic, Selma Martin, Jane Montgomery, Casey Eaton, Elizabeth Vyas, Monika Muranen, Taru E. Hidalgo, Manuel Bockorny, Bruno affil: Beth Israel Deaconess Medical Center, Boston, MA sug: pubtype: Academic Journal doctype: Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|